Showing results (41-50 of 181) with videos related to

Sort By:
Pageof 19
International Journal of Cancer|December 2, 1991
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liverJ J Oudejans, R J Slebos, F A Zoetmulder, et al.
International Journal of Cancer|April 22, 1991
Allele-specific detection of K-ras oncogene expression in human non-small-cell lung carcinomasR J Slebos, G G Habets, S G Evers, et al.
Therapeutic Drug Monitoring|January 22, 2002
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimenA D Huitema, R A Mathôt, M M Tibben, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantroneL T Vlasveld, B G Taal, B B Kroon, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 27, 2001
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamideA D Huitema, R A Mathôt, M M Tibben, et al.
British Journal of Cancer|June 12, 2003
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experienceJ G Schrama, M J Holtkamp, J W Baars, et al.
International Journal of Cancer|May 1, 1994
Association of H-ras mutations with adenocarcinomas of the parotid glandH K van Halteren, B Top, W J Mooi, et al.
Anticancer Research|August 21, 2003
Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacyJ G Schrama, M M de Boer, J W Baars, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|June 1, 1992
A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissuesR J Slebos, L Boerrigter, S G Evers, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in manM H Beneken genaamd Kolmer, S Rodenhuis, J C van de Grampel, et al.
Pageof 19